CUAMC
KNTE

China Universal Asset Management Company’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

China Universal Asset Management Company’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,201
Closed -$1.68K – 496
2023
Q3 		$1.68K Buy
1,201
+590
+97% +$1.42K ﹤0.01% 440
2023
Q2 		$1.85K Buy
611
+13
+2% +$50 ﹤0.01% 430
2023
Q1 		$3.74K Buy
598
+150
+33% +$914 ﹤0.01% 395
2022
Q4 		$2.73K Buy
448
+34
+8% +$277 ﹤0.01% 353
2022
Q3 		$5K Buy
+414
New +$5.42K ﹤0.01% 281

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

China Universal Asset Management Company's KNTE Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 1,201 shares — an estimated $1.68K sold.

China Universal Asset Management Company first reported a position in KNTE in Q3 2022 and held it in 5 quarters. The position peaked at $5K in Q3 2022. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 1,201 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $1.68K.
  • China Universal Asset Management Company first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Kinnate Biopharma Inc. Common Stock position peaked at $5K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.